Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known chronic renal insufficiency of at least 4 weeks duration; CKD stage at least 3 or higher~* Male and female patients, age: \>=18~* Patients who are naïve to ESA treatment or previously ESA treated after 3 months of ESA-free period (i.v. or s.c.)~* Patients with symptomatic anemia, defined as Hb level below 11.0 g/dL and not lower than or equal to 7.5 g/dL on at least 2 visits during the screening period~* Adequate iron status, serum ferritin \>= 100 µg/L or transferrin saturation \>= 20%~* Ability to follow study instructions and likely to complete all required visits and compliant with subcutaneous administration~* Written informed consent of the patient.~Exclusion Criteria:~* Anemia of non-renal causes~* Therapy with immunosuppressants (other than corticosteroids for chronic treatment) within 3 months before screening and during the study for patients with renal allograft in place or other chronic conditions (e.g. lupus erythematosus, rheumatic arthritis)~* Patients previously treated with chronic dialysis within the last 6 months (exception: one session of acute dialysis)~* Patients with acute deterioration of renal function during the screening phase according to the investigator's judgment~* Patients receiving any RBC/whole blood transfusion during the screening period~* Primary hematological disorder (e.g. myeloma, myelodysplastic syndrome, sickle cell anemia, hematological malignancy, hemolytic anemia)~* Evidence of uncontrolled diabetes mellitus (HbA1c \> 10 % at visit -2)~* Evidence of severe hepatic dysfunction (e.g. ALT and/or AST above 2x upper limit of normal range; or gamma-GT above 3x upper limit of normal range)~* Clinical evidence of current uncontrolled or symptomatic hyperparathyroidism, defined as parathyroid hormone \> 500 ng/L at visit -2.~* Uncontrolled hypertension, defined as a systolic blood pressure of \>= 160 mmHg and a diastolic blood pressure measurement \>= 100 mmHg (average of two values with at least one day between measurements)~* Congestive heart failure and/or angina pectoris \[New York Heart Association (NYHA) class III and IV\]~* History of stroke or myocardial infarction during the last 6 months prior to visit -2~* Ongoing treatment with phenprocoumon or other cumarin derivates~* Thrombocytopenia (platelet count \<100.000/µL) or leucopenia (white blood cell count \< 2.000/µL)~* Gastrointestinal bleeding within the last 6 months prior to visit -2 or hemolysis~* Evidence of acute or chronic infection by a C-reactive protein value of \> 30 mg/L~* Suspicion or known PRCA (pure red cell aplasia)~* Previously diagnosed HIV or acute hepatitis infection~* History of epilepsy or epileptic seizures or treatment for epilepsy within the past 6 months prior to screening~* Planned major surgery (with expected high blood loss) during the next 3 months or major surgery within the previous 3 months (except laser photocoagulation, access surgery)~* Clinical evidence of active malignant diseases within the last 5 years (except non-melanoma skin cancer)~* Pregnancy, breastfeeding women or women not using a highly effective birth control method (e.g. implants, injectables, combined oral contraceptives, IUD, sexual abstinence, vasectomised partner)~* Known history of severe drug related allergies (e.g. anaphylactic shock)~* Known allergy to one of the ingredients of the test product or hypersensitivity to mammalian-derived products~* Known or suspicion of any non-compliance with respect to subcutaneous treatment~* Simultaneous participation in another clinical study or participation in a study in the month preceding visit-2 or previously randomized in this study~* Participation in another ESA study in the 3 months preceding visit -2~* Any other condition which at the investigator's discretion may put the patient at risk or which may confound the study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): HX575, EPO HEXAL
- 2 (Type: ACTIVE_COMPARATOR): ERYPO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues